Dose optimization of BTX-9341, a first-in-class CDK4/6 bifunctional degrader, in CDK4/6 inhibitor-pretreated HR+/HER2- advanced/metastatic breast cancer

BTX-9341 - BioTheryX

fulvestrant - Generic mfg.

https://oncologypro.esmo.org/congress-resources/esmo-breast-cancer-2026?presentation=n421ro___dose_optimization_of_btx_9341__a_first_in

M.P. Goetz1; A. Patnaik2; M.B. Block3; W.B. McKean4; M. Cristofanilli5; H. Majeski6; A. Shakya6; P. Rajagopalan6; C. Deshpande6; T. Marmon6; D. Powell-Hopitzan6; A.H. Chourasia7; R. Urbanski6; R. Layman8

Feb 25, 2026